EuBiologics Co (XKRX:206650) EBIT per Share : ₩-8.62 (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is EuBiologics Co EBIT per Share?

EuBiologics Co's EBIT per Share for the three months ended in Sep. 2024 was ₩448.34. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ₩-8.62.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for EuBiologics Co's EBIT per Share or its related term are showing as below:

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of EuBiologics Co was -0.10% per year. The lowest was -6.60% per year. And the median was -3.35% per year.

XKRX:206650's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 6.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

EuBiologics Co's EBIT for the three months ended in Sep. 2024 was ₩16,417 Mil.

EuBiologics Co EBIT per Share Historical Data

The historical data trend for EuBiologics Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EuBiologics Co EBIT per Share Chart

EuBiologics Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-11.09

-2,086.16

-845.93

-77.26

-372.24

EuBiologics Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-85.42	-328.05	-92.05	-36.86	448.34

EuBiologics Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

EuBiologics Co's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-13559.766	/	36.428
=	-372.23

EuBiologics Co's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	16416.783	/	36.617
=	448.34

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-8.62

EuBiologics Co (XKRX:206650) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

EuBiologics Co EBIT per Share Related Terms

Thank you for viewing the detailed overview of EuBiologics Co's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

EuBiologics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EuBiologics Co Ltd (XKRX:206650) » Definitions » EBIT per Share

Traded in Other Exchanges

N/A

Address

6F Bomnal-A-Chim B/D Mabang-ro 8, Seocho-gu, Seoul, KOR, 06778

Website

http://www.eubiologics.com

EuBiologics Co Ltd is a biopharmaceutical company, which develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine, Inaba Cairo, and among others.

EuBiologics Co Headlines

No Headlines